◀ Back to STAT3
IL1B — STAT3
Pathways - manually collected, often from reviews:
Text-mined interactions from Literome
Ng et al., J Biol Chem 2001
(Hypertrophy...) :
Either inhibitor alone prevented STAT3 phosphorylation, implicating ERKs and p38 ( MAPK ) in the delayed
STAT3 response to
IL-1 beta
Mancini et al., Neurosci Lett 2003
:
In the same cell type neither
IL-1beta dependent SAPK activation nor IL-6 induced
STAT3 phosphorylation is affected by the drug
Park et al., Cytokine 2005
(Carcinoma, Medullary...) :
IL-1beta induces expression of leukemia inhibitory factor (LIF) and activation of
STAT3 via the MEK/ERK pathway ... This activation of STAT3 could be abrogated by treatment with anti-LIF neutralizing antibody or anti-gp130 blocking antibody, indicating that induction of LIF expression is sufficient and essential for
STAT3 activation by
IL-1beta
Lafarge et al., BMC molecular biology 2007
:
In
response to
IL1beta , or IL10, the levels of phosphorylated NF-kappaB and
STAT3 -- respectively -- increased significantly for all the studied cell types
Kanda et al., Endocrinology 2008
:
IL-1beta induced serine phosphorylation of inhibitory kappaBalpha, STAT1, and
STAT3
Samavati et al., Mol Immunol 2009
(Inflammation) :
STAT3 tyrosine phosphorylation is
critical for
interleukin 1 beta and interleukin-6 production in response to lipopolysaccharide and live bacteria ... A newly developed
STAT3 specific inhibitor ( stattic ) blocked LPS mediated STAT3 tyrosine phosphorylation and
led to inhibition of LPS mediated
IL-1beta and IL-6 production but not TNF-alpha production
Ravichandran et al., Indian J Exp Biol 2011
(Carcinoma...) :
Detailed molecular analyses showed that
IL-1beta increased expression of phosphorylated STAT1 ( Tyr701 and Ser727 ) and
STAT3 ( Tyr705 and Ser727 ) both in total cell lysates and nuclear lysates